Integrated DNA Technologies partners with Hamilton to automate next-generation sequencing workflows
Integrated DNA Technologies (IDT) has announced a strategic partnership with Hamilton Company to develop automated comprehensive genomic profiling workflows for cancer research and other genomic applications. The collaboration will integrate IDT’s customisable NGS research components with Hamilton’s precision liquid handling platforms.
Global automation agreement
The partnership establishes a worldwide agreement to create automation scripts for IDT’s xGen and Archer NGS products, designed for use on Hamilton’s Microlab STAR and NIMBUS liquid handling systems. This integration aims to provide laboratories with enhanced capabilities for identifying critical biomarkers in cancer research whilst offering flexibility in workflow design.
According to IDT President Ajay Gannerkote, the collaboration addresses limitations inherent in standardised approaches. “By pairing IDT’s flexible NGS solutions with Hamilton’s automation expertise, we’re removing constraints that may arise from one-size-fits-all approaches so labs can consistently and reliably accelerate their discoveries with confidence, precision and speed, at whatever scale their work demands,” he said.
Enhanced scalability for research laboratories
The automated workflows are intended to reduce manual processing time, allowing researchers to focus on data analysis and interpretation. The partnership supports IDT’s broader portfolio of platform-agnostic NGS solutions for solid tumour and haematological malignancy research.
Michael Mouradian, Hamilton’s Vice President of Scientific Strategy and Market Development, emphasised the technical benefits of the collaboration. “By combining Hamilton’s precision engineering and trusted liquid handling platforms with IDT’s innovative assay solutions, we are enabling laboratories to achieve greater scalability, consistency, and efficiency in their genomic discoveries,” he said.
The automated solutions are designed to accommodate varying laboratory scales and research requirements, from small-scale studies to high-throughput applications. IDT’s NGS portfolio encompasses sample-to-report assay offerings that can be adapted to different sequencing platforms and research objectives.
